| Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer M Desbois, AR Udyavar, L Ryner, C Kozlowski, Y Guan, M Dürrbaum, ... Nature communications 11 (1), 5583, 2020 | 123 | 2020 |
| Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer AR Udyavar, MD Hoeksema, JE Clark, Y Zou, Z Tang, Z Li, M Li, H Chen, ... BMC systems biology 7, 1-16, 2013 | 85 | 2013 |
| Novel hybrid phenotype revealed in small cell lung cancer by a transcription factor network model that can explain tumor heterogeneity AR Udyavar, DJ Wooten, M Hoeksema, M Bansal, A Califano, L Estrada, ... Cancer Research 77 (5), 1063-1074, 2017 | 74 | 2017 |
| DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway S Ocak, H Yamashita, AR Udyavar, AN Miller, AL Gonzalez, Y Zou, ... Oncogene 29 (48), 6331-6342, 2010 | 52 | 2010 |
| Subtle affinity-enhancing mutations in a myelin oligodendrocyte glycoprotein-specific TCR alter specificity and generate new self-reactivity A Udyavar, R Alli, P Nguyen, L Baker, TL Geiger The Journal of Immunology 182 (7), 4439-4447, 2009 | 50 | 2009 |
| Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy A Udyavar, TL Geiger Archivum immunologiae et therapiae experimentalis 58, 335-346, 2010 | 36 | 2010 |
| ARC-8: Phase I/Ib study to evaluate safety and tolerability of AB680+ chemotherapy+ zimberelimab (AB122) in patients with treatment-naive metastatic pancreatic adenocarcinoma … GA Manji, ZA Wainberg, K Krishnan, N Giafis, A Udyavar, CS Quah, ... Journal of Clinical Oncology 39 (3_suppl), 404-404, 2021 | 24 | 2021 |
| Targeting CD73 with AB680 (quemliclustat), a novel and potent small-molecule CD73 inhibitor, restores immune functionality and facilitates antitumor immunity D Piovesan, JBL Tan, A Becker, J Banuelos, N Narasappa, D DiRenzo, ... Molecular Cancer Therapeutics 21 (6), 948-959, 2022 | 18 | 2022 |
| Genomic alterations associated with recurrence and TNBC subtype in high-risk early breast cancers TR Wilson, AR Udyavar, CW Chang, JM Spoerke, J Aimi, HM Savage, ... Molecular Cancer Research 17 (1), 97-108, 2019 | 18 | 2019 |
| Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4‐driven transcriptional state W Yan, CY Chung, T Xie, M Ozeck, TC Nichols, J Frey, AR Udyavar, ... Molecular Oncology 16 (6), 1309-1328, 2022 | 17 | 2022 |
| Phase I evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies J Powderly, A Spira, R Gutierrez, D DiRenzo, A Udyavar, JJ Karakunnel, ... Annals of Oncology 30, v493, 2019 | 15 | 2019 |
| Altered TGF-α/β signaling drives cooperation between breast cancer cell populations OE Franco, DR Tyson, KC Konvinse, AR Udyavar, L Estrada, V Quaranta, ... The FASEB Journal 30 (10), 3441, 2016 | 11 | 2016 |
| Abstract P2-09-13: molecular characterization of tumors from metastatic TNBC patients treated with atezolizumab (atezo) L Molinero, CW Chang, A Udyavar, M Fasso, C O'Hear, L Emens, C Cruz, ... Cancer Research 78 (4_Supplement), P2-09-13-P2-09-13, 2018 | 9 | 2018 |
| Abstract CT129: ARC-3: Updated results of etrumadenant (AB928)+ modified FOLFOX-6 (mFOLFOX-6) in metastatic colorectal cancer (mCRC) patients M Cecchini, C Quah, S Liu, R Woloski, A Udyavar, M Giannakis Cancer Research 81 (13_Supplement), CT129-CT129, 2021 | 6 | 2021 |
| Characterization of AB154, a humanized, non-depleting α-TIGIT antibody undergoing clinical evaluation in subjects with advanced solid tumors AE Anderson, A Lopez, A Udyavar, N Narasappa, S Lee, D DiRenzo, ... Proceedings of the SITC Annual Meeting, National Harbor, MD, USA, 6-10, 2019 | 4 | 2019 |
| Altered pan-Ras pathway and activating mutations in EGFR result in elevated CD73 in multiple cancers AR Udyavar, D DiRenzo, D Piovesan, D Ashok, AE Anderson, SW Young, ... AACR abstract 2526, 2019 | 4 | 2019 |
| Abstract B27: Phenotypic plasticity and heterogeneity in small cell lung cancer (SCLC): Novel molecular subtypes and potential for targeted therapy. AR Udyavar, M Hoeksema, K Diggins, J Irish, PP Massion, V Quaranta Clinical Cancer Research 20 (2_Supplement), B27-B27, 2014 | 4 | 2014 |
| Antitumor activity of T cells expressing a novel anti-folate receptor alpha (FOLR1) costimulatory antigen receptor (CoStAR) in a human xenograft murine solid tumor model and … OR Moon, Y Qu, MG King, M Mojadidi, C Chauvin-Fleurence, C Yarka, ... Journal of Clinical Oncology 40 (16_suppl), 2535-2535, 2022 | 3 | 2022 |
| Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B A Daemen, AR Udyavar, T Sandmann, C Li, LJW Bosch, W O’Gorman, ... Plos one 16 (12), e0262198, 2021 | 3 | 2021 |
| Abstract A46: CD73 inhibition enhances the effect of anti-PD-1 therapy on KRAS-mutated pancreatic cancer model TM Le, A Udyavar, W Kim, AE Cho, L Li, D DiRenzo, B Rosen, MJ Walters, ... Cancer Immunology Research 8 (3_Supplement), A46-A46, 2020 | 3 | 2020 |
